Tempest Therapeutics (TPST) Asset Writedowns and Impairment (2016 - 2018)

Tempest Therapeutics has reported Asset Writedowns and Impairment for 3 years, with the latest figure at -$1.3 million in Q3 2018.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to -$1.3 million in Q3 2018, while the trailing twelve-month figure through Dec 2018 was -$218000.0 (down 113.97% YoY) and the FY2018 annual result came in at $871000.0, down 36.14% from the prior year.
• Asset Writedowns and Impairment slipped to -$1.3 million in Q3 2018 per TPST's latest filing, from $1.1 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $1.1 million in Q4 2017 and troughed at -$1.3 million in Q3 2018.
• A 3-year average of $57250.0 and a median of $223500.0 in 2016 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 657.82% in 2017, down 657.82% in 2017.
• Over 3 years, Asset Writedowns and Impairment stood at $147000.0 in 2016, then surged by 657.82% to $1.1 million in 2017, then sank by 219.57% to -$1.3 million in 2018.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$1.3 million, $1.1 million, and $300000.0 for Q3 2018, Q4 2017, and Q2 2017 respectively.